Entellus Medical Inc (ENTL) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $-0.27 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.08. Analysts had a consensus of $-0.35. The company posted revenue of $18.73 million in the period, compared to analysts expectations of $18.57 million. The company’s revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.15 EPS.
Entellus Medical Inc closed down -0.09 points or -0.51% at $17.52 with 30,850 shares getting traded on Tusday. Post opening the session at $17.57, the shares hit an intraday low of $17.39 and an intraday high of $17.81 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Aug 2, 2016, Kevin L Mensink (Vice President, Marketing) sold 8,100 shares at $17.63 per share price. According to the SEC, on Jul 19, 2016, Timothy B Petrick (VP, Research and Development) sold 3,000 shares at $18.15 per share price. On Feb 4, 2016, Karen E Peterson (officer ) sold 10,000 shares at $17.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Entellus Medical Inc. is a medical technology company. The Company is focused on the design development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear nose and throat (ENT) physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses. Its XprESS family of products includes its XprESS Pro device its XprESS LoProfile device and its XprESS Ultra device. The Company markets its products in the United States and Canada and sells its products through a direct sales force in the United States.